Immunomodulating Drugs For The Treatment Of Cancer

Immunomodulatory (IMiDs) drugs are a new class of anticancer agents that has made a tremendous impact on the treatment of patients with various malignant diseases, including blood cancers and several cancers of the solid organs. Their popularity in prescribing is based on several important characteristics including: (1) oral bioavailability, (2) non-chemotherapeutic, (3) extremely well-tolerated in all age groups, (4) ability to activate patient's own immune response against cancer, (5) ease of combination with other agents such as chemotherapy resulting in higher responses as well as (6) variability of anticancer activity and a number of cancers. While there is a lot of literature published on these agents, there is no textbook that provides a comprehensive resource for clinicians and researchers regarding these agents and their rapidly emerging role in cancer medicine.The clinical applications of these agents are not limited to oncologists and hematologists, but also impact primary care doctors who care for these patients. Furthermore, new investigations are defining the role of these agents in non-malignant disorders as well. Immunomodulating Drugs for the Treatment of Cancer brings the most current information on these novel compounds to clinicians and scientists involved in the care of cancer patients.A companion website offers the fully searchable text and an image bank

Part 1: INTRODUCTION 1: Introduction to the Immunomodulatory Agents for the Treatment of Malignant Conditions Part 2: PRECLINICAL DEVELOPMENT 2: The Mechanism of Action of the Immunomodulating Drugs (IMiDs) Compounds Part 3: CLINICAL DEVELOPMENT 3: Overview: Clinical Impact of IMiDs in Oncology 4: Thalidomide for Relapsed or Refractory Myeloma 5: Role of IMiDs as Initial Therapy for Multiple Myeloma 6: Role of Immunomodulatory Drugs for the Treatment of Newly Diagnosed Multiple Myeloma in Elderly Patients 7. IMiDs as Maintenance Therapy in Multiple Myeloma 8: Lenalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma 9: IMiDs and Stem Cell Transplantation in Multiple Myeloma 10: IMiDs in Waldenstrom's Macroglobulinemia 11: Lenalidomide for the Treatment of Myelodysplastic Syndrome 12: Thalidomide and Lenalidomide for the Treatment of Primary Myelofibrosis 13: Immunomodulatory Drugs for the Treatment of Chronic Lymphocytic Leukemia 14: Lenalidomide in Combination with Other Novel Agents: A New Diimension in Myeloma Therapeutics 15: Lenalidomide for Non-Hodgkin's Lymphoma 16: Clinical Efficacy of Immunomodulatory Drugs in Amyloidosis 17: Immunomodulating Drugs for the Treatment of Prostate Cancer 18: Pomalidomide in Cancer Therapy Part 4: COMPLICATIONS 19: IMiDs-Associated Toxicities and Their Management 20: Toxicity Associated with the Immunomodulating Agents in Patients with Chronic Lymphocytic Leukemia